BG07 Once in a blue moon?

Vidya Madhwapathi,Simon Tso

DOI: https://doi.org/10.1093/bjd/ljae090.253

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract An 80-year-old woman with a background of Hodgkin disease, hypertension and arthritis was diagnosed with bullous pemphigoid (BP) following skin biopsy. She was managed as a dermatology outpatient with skin-directed therapies (clobetasol propionate ointment and emollients) and doxycycline 100 mg once daily (due to renal function). Following a flare of BP, the accident and emergency department added oral prednisolone 40 mg once daily with proton pump inhibitor cover, which was gradually weaned down, but disease control remained suboptimal at prednisolone 20 mg once daily. She was later admitted as an inpatient due to new-onset delirium and acute chronic renal impairment attributable to hyponatraemia and steroid-induced delirium. Despite supervised weaning of oral prednisolone (with cortisol monitored to avoid Addisonian crisis) and commencement of oral dapsone 50 mg once daily (on a background of normal glucose-6-phosphate dehydrogenase level and baseline methaemoglobin level), the delirium persisted. Full-body computed tomography was performed, showing small-vessel ischaemia. A methaemoglobin level performed after dermatology review showed an increased level of 14.2%. Methylene blue was commenced and dapsone stopped. The patient continued to deteriorate despite ward-based care. She was discharged for palliation and passed away a few weeks later. Dapsone is a drug with immunosuppressive properties, used in a wide variety of dermatological conditions including BP, pyoderma gangrenosum and vasculitis. Methaemoglobinaemia is a well-known, but uncommon side-effect. Attributing causation for this patient’s symptoms to prednisolone alone is difficult, as her symptoms started 4 weeks after, at a dose of 20 mg. Fully attributing them to dapsone is also difficult, as the symptoms had started before its initiation. However, it is likely multifactorial. BP itself, addition of immunosuppressive BP treatment, polypharmacy and subsequent methaemoglobinaemia tipped the delicate balance in a patient of advancing age, with known small-vessel ischaemia and other comorbidities. This difficult case highlights the challenges and complexities of managing dermatological conditions and the use of immunosuppression in an increasingly older population. The number of people aged ≥ 85 years in the UK was estimated to be 1.7 million in 2020 (2.5% of the UK population) and this is projected to almost double to 3.1 million by 2045 (4.3% of the UK population). The issues arising in this case will become more commonplace for dermatologists. This case emphasizes the need for working closely with colleagues caring for older patients, and for consideration of rare side-effects of medications as a contributor to delirium.

dermatology